Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this signal seeking study was to determine whether treatment with dovitinib
(TKI258) demonstrated sufficient efficacy in select pathway-activated solid tumors and/or
hematologic malignancies to warrant further study.